Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
- Resource Type
- Case Study
- Authors
- Anghelina, Mirela; Rogers, Kerry A.; Blachly, James S.; Lucas, David M.; Jones, Jeffrey A.; Williams, Katie; Oakes, Christopher; Grever, Michael R.; Andritsos, Leslie A.; Grieselhuber, Nicole R.; Roychowdhury, Sameek; Reeser, Julie W.; Timmers, Cynthia D.; Freud, Aharon G.; Lozanski, Gerard; Jones, Dan
- Source
- Leukemia & Lymphoma. Apr2018, Vol. 59 Issue 4, p1008-1011. 4p.
- Subject
- *HAIRY cell leukemia
*ANTINEOPLASTIC agents
*IMMUNOGLOBULIN heavy chains
*MITOGEN-activated protein kinases
*HOMOGRAFTS
- Language
- ISSN
- 1042-8194
The article presents case study of a 52-year-old man with splenomegaly and lymphocytosis and was diagnosed with variant hairy cell leukemia (vHCL). It is mentioned that the patient was administered with trametinib for the treatment of IGHV4-34 and MAP2K1-mutation. The article further adds that the patient experienced disease relapse after allogeneic transplantation and developed skin nodules and generalized skin rash.